By Mikkael Sekeres, MD, MS, and Timothy Gilligan, MD
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
We’re meeting you for the first time, soon after your primary care doctor or surgeon has sat down with you, or called, to tell you some terrible news: You have cancer.
We are the oncologists, and we want to help. We want to discuss your diagnosis, what it means and what the options are for treatment. We’d like to give you a clear map of what your life might look like over the next few months as we fight along with you to minimize the amount of this awfulness, even if temporarily, from your body.
But one of the biggest problems we face is that we often can’t figure out what our patients would like to know about their prognosis. Even when we ask.
Read the full New York Times column by Dr. Sekeres, Director of Cleveland Clinic Cancer Center’s Leukemia Program, and Dr. Gilligan, Taussig Cancer Institute’s Vice-Chair for Education and Director of Coaching at the Center for Excellence in Healthcare Communication.
Photo Credit ©Russell Lee
Timing and type of side effects differ greatly from chemotherapy
Dedicated multidisciplinary teams support 84 ultra-rare cancers
Sessions explore treatment advances and multidisciplinary care
New research from Cleveland Clinic helps explain why these tumors are so refractory to treatment, and suggests new therapeutic avenues
Combination of olaparib and carboplatin results in complete durable response for a patient with BRCA2 and “BRCAness” mutations
Early communication between oncologists and ophthalmologist warranted
Case-based course delves into latest treatment approaches
Long-term relationship building and engagement key to gaining community trust